MaxCyte, Inc. Upcoming Investor Conferences (3691B)

TIDMMXCT TIDMTTM

RNS Number : 3691B

MaxCyte, Inc.

02 June 2023

MaxCyte to Participate in Upcoming Investor Conferences

Rockville, MD, June 2, 2023 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell -engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the following investor conferences:

   --    William Blair 43(rd) Annual Growth Stock Conference 

Thursday, June 8 at 8:00 a.m. Central Time

   --    TD Cowen 2(nd) Annual Tools/Dx Revolution 

Monday, June 26(th) at 3:10 PM Pacific Time

A live and archived webcast of the William Blair Presentation will be available on the "Events" section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM), GTx(TM) and VLx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn .

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

[phone]

[e-mail]

US Media Relations

Spectrum Seismic Collaborative

Valerie Enes

[phone]

[e-mail]

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

[phone]

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

[phone]

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKDBKDBKDOAK

(END) Dow Jones Newswires

June 02, 2023 02:00 ET (06:00 GMT)